ArticleCurrent treatment options in neurology2015
Current treatment and management of pyridoxine-dependent epilepsy.
Article in Current treatment options in neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 52 citations in OpenAlex.
- Is Vitamin B6 a Precision Therapy for Neonatal Seizures?Neurology international · 2025Review
- Neonatal Refractory Seizures and Hyperammonemia in a Neonate With ALDH7A1 Deficiency.Clinical case reports · 2025Article
- Structure Elucidation for MALDI Mass Spectrometry Imaging Using Infrared Ion Spectroscopy.Analytical chemistry · 2025Article
- Clinical Profile, Genotypes, and Outcomes in Children with Pyridoxine Dependent Epilepsy (PDE): A Single Center Experience from Southern India.Indian pediatrics · 2025Article
- Article
- [Phenotype of infantile epileptic spasm syndrome in pyridoxin-dependent epilepsy].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2024Article
- Pyridoxine Therapy: Not Just the Dose, the Duration Matters Too.Journal of pediatric genetics · 2023Article
- Pyridoxine-Dependent Epilepsy: A Treatable Epilepsy Syndrome Presenting with Dystonia and Congenital Cataracts with a Novel Mutation.Movement disorders clinical practice · 2023Article
- Personalized medicine for rare neurogenetic disorders: can we make it happen?Cold Spring Harbor molecular case studies · 2022Article
- Pyridoxine-Dependent Epilepsy and Antiquitin Deficiency Resulting in Neonatal-Onset Refractory Seizures.Brain sciences · 2021Review
- Clinical and biochemical outcome of a patient with pyridoxine-dependent epilepsy treated by triple therapy (pyridoxine supplementation, lysine-restricted diet, and arginine supplementation).Acta neurologica Belgica · 2021Article
- Inherited Developmental and Epileptic Encephalopathies.Neurology international · 2021Review
- Metabolic Epilepsy.Indian journal of pediatrics · 2021Review
- Analysis of the Phenotypic Variability as Well as Impact of Early Diagnosis and Treatment in Six Affected Families WithFrontiers in genetics · 2021Article
- Article
- Treatable Genetic Metabolic Epilepsies.Current treatment options in neurology · 2017Review
- Inborn Errors of Metabolism and Epilepsy: Current Understanding, Diagnosis, and Treatment Approaches.International journal of molecular sciences · 2017Review
- Genetic Testing in Pediatric Epilepsy.Current neurology and neuroscience reports · 2017Review
- [Intermittent convulsions for 1.5 years and psychomotor retardation in a girl].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2017Article
- Pyridoxine-dependent epilepsy: report on three families with neuropathology.Metabolic brain disease · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementPyridoxine-dependent epilepsy (PDE) is a rare autosomal recessive disorder and is considered as a prototypical form of metabolic epilepsy. Characterized by recurrent seizures in the prenatal, neonatal, and/or postnatal periods that are resistant to conventional anti-epileptic drugs, PDE is responsive to pharmacological dosages of pyridoxine. Presently, however, there are no clear dose recommendations for long-term treatment. While pyridoxine supplementation is the first line of treatment and should be initiated in all confirmed PDE patients at an early age, various other treatment strategies are emerging. These include a lysine-restricted diet and arginine fortification. These will be discussed in light of current evidence, together with recommendations for best management of patients with this rare but treatable metabolic epilepsy, and future research and collaborative efforts, including the International PDE Consortium.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.